A. Bacchiocchi

发表

Plasma Markers for Identifying Patients with Metastatic Melanoma

S. Ariyan, Y. Kluger, R. Halaban, 2011, Clinical Cancer Research.

Incidence of the V600K mutation among melanoma patients with BRAF mutations, and potential therapeutic response to the specific BRAF inhibitor PLX4032

S. Ariyan, R. Halaban, M. Sznol, 2010, Journal of Translational Medicine.

Integrative molecular and clinical profiling of acral melanoma links focal amplification of 22q11.21 to metastasis

Aaron M. Newman, James E. Clune, S. Ariyan, 2022, Nature Communications.

Integrative molecular and clinical profiling of acral melanoma identifies LZTR1 as a key tumor promoter and therapeutic target

Aaron M. Newman, James E. Clune, S. Ariyan, 2021, bioRxiv.

MERTK controls melanoma cell migration and survival and differentially regulates cell behavior relative to AXL

T. Boggon, J. Platt, Antonella Bacchiocchi, 2013, Pigment cell & melanoma research.

Early B cell changes predict autoimmunity following combination immune checkpoint blockade

Aaron M. Newman, A. Newman, M. Dhodapkar, 2018, The Journal of clinical investigation.

Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma

Matthew J. Davis, S. Ariyan, K. Kidd, 2012, Nature Genetics.

CD4 T cells and toxicity from immune checkpoint blockade

Aaron M. Newman, A. Newman, A. Chaudhuri, 2023, Immunological reviews.

Genotype-selective combination therapies for melanoma identified by high-throughput drug screening.

M. Held, C. G. Langdon, J. Platt, 2013, Cancer discovery.

Exome sequencing identifies recurrent mutations in NF1 and RASopathy genes in sun-exposed melanomas

S. Ariyan, Shuangge Ma, S. Mane, 2015, Nature Genetics.

Exome sequencing identifies recurrent somatic RAC 1 mutations in melanoma

Matthew J. Davis, S. Ariyan, K. Kidd, 2016 .

PLX4032, a selective BRAFV600E kinase inhibitor, activates the ERK pathway and enhances cell migration and proliferation of BRAFWT melanoma cells

Michael Krauthammer, Yuval Kluger, Fabio Parisi, 2010, Pigment cell & melanoma research.

Survey of tyrosine phosphorylated receptors by RTK capture array analysis in untreated melanoma cell lines

R. Halaban, M. Krauthammer, Antonella Bacchiocchi, 2011 .

Preexisting MEK1 exon 3 mutations in V600E/KBRAF melanomas do not confer resistance to BRAF inhibitors.

J. Sosman, R. Halaban, A. Ribas, 2012, Cancer discovery.

MicroRNA signatures differentiate melanoma subtypes

S. Ariyan, F. Slack, J. Weidhaas, 2011, Cell cycle.

Dynamic changes of circulating soluble PD-1/PD-L1 and its association with patient survival in immune checkpoint blockade-treated melanoma.

R. Halaban, H. Risch, Antonella Bacchiocchi, 2023, International immunopharmacology.

Interlesional diversity of T cell receptors in melanoma with immune checkpoints enriched in tissue-resident memory T cells.

S. Ariyan, Krishna Kadaveru, M. Dhodapkar, 2016, JCI insight.

Interferon-stimulated neutrophils as a predictor of immunotherapy response

S. Shen-Orr, Y. Shaked, I. Kamer, 2023, Cancer cell.

Chemiexcitation of melanin derivatives induces DNA photoproducts long after UV exposure

R. Halaban, E. Bechara, K. Wakamatsu, 2015, Science.

A Variant in a MicroRNA Complementary Site in the 3′UTR of the KIT Oncogene Increases Risk of Acral Melanoma

S. Ariyan, F. Slack, K. Kidd, 2010, Oncogene.

Phosphoproteomic Screen Identifies Potential Therapeutic Targets in Melanoma

R. Halaban, M. Krauthammer, Antonella Bacchiocchi, 2011, Molecular Cancer Research.